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Abstract
Objectives—Interventions to improve adult vaccination uptake in primary care have met with 
limited success, raising questions about whether the benefits to patients are worth the time and 
resources necessary to implement them. Here we examine the cost effectiveness of an intervention 
to increase pneumococcal, influenza and pertussis-containing vaccine uptake among adults ≥65 
years of age in primary care practices.
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Design—Markov decision analysis model, estimating the cost-effectiveness of the 4 Pillars™ 
Practice Transformation Program compared with no intervention.
Setting—Diverse primary care practices in 2 US cities
Participants—Clinical trial patients aged 65 years and older. Vaccination rates and intervention 
costs were derived from a randomized controlled cluster trial. Other parameters were derived from 
the medical literature and CDC data. All parameters were individually and simultaneously varied 
over their distributions.
Measurements—Quality adjusted life years (QALYs), public health outcomes, and costs
Results—With the intervention program and extrapolating over 10 years, there would be ~60,920 
fewer influenza cases, 2,031 fewer pertussis cases, and 13,842 fewer pneumococcal illnesses 
among adults ≥65 years. Compared to no intervention, total per-person vaccination and illness 
costs with the intervention were $1.60 higher with a concurrent increase in effectiveness of 0.0031 
QALYs, or $512 per QALY gained. In sensitivity analyses, no individual parameter variation 
caused the intervention to cost >$20,000 per QALY gained.
Conclusions—Implementing an intervention based on the 4 Pillars™ Practice Transformation 
Program is a cost-effective undertaking in primary care practices for patients ≥65 years old with 
predicted public health benefits.
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Introduction
The 4 Pillars™ Practice Transformation Program, also known as the 4 Pillars™ Toolkit 
(Toolkit), is a primary care practice improvement aid focused on changing behavior using 
evidence-based strategies (1, 2) that are organized into four domains. The pillars are: 1. 
Convenient vaccination services; 2. Communication with patients about the importance of 
immunization and the availability of vaccines; 3. Enhanced office systems to facilitate 
immunization; and 4. Motivation through an office immunization champion who monitors 
progress and encourages adherence to vaccination-promoting office procedures to improve 
vaccine uptake (3). The Toolkit has been tested in several trials and found to be moderately 
effective for increasing immunization rates in adults (3, 4) and children (5). The question 
remains whether the benefits from an intervention to improve adult vaccination rates are 
worth the effort of implementing a set of long-term patient-, provider-, and office system 
changes. From the provider’s perspective, there is a financial incentive to increase vaccine 
uptake, as the Center for Medicare and Medicaid Services has made reporting of influenza 
and pneumococcal vaccines a requirement for providers to avoid negative payment 
adjustments (6). Moreover, in some states, administration fees adequately reimburse 
providers for offering adult vaccines. Conversely, there are costs associated with 
implementing some of the Toolkit strategies such as educating and training staff, writing 
standing order protocols, establishing new policies, purchasing vaccine informational 
materials, and making or sending vaccination reminders.
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The Toolkit is an online source of evidence-based practices for implementing a quality 
control project that contains background information on vaccines, case studies and best 
practices, strategies for making changes in each of the 4 Pillars’ domains, resources, links to 
other reliable vaccination sites and a dashboard to assist practices with choosing strategies, 
mapping the change process and tracking progress. The purpose of this study was to 
examine the cost effectiveness of an intervention to increase pneumococcal vaccine uptake 
among adults ≥65 years of age in primary care practices using the Toolkit. A Markov 
decision analysis model was used to estimate the cost effectiveness of using the Toolkit to 
improve vaccination rates compared with no intervention.
Methods
Vaccination rates and intervention costs were derived from a randomized controlled cluster 
trial conducted in two U.S. cities (Pittsburgh and Houston) among diverse populations and 
medical practice settings. (4) The trial was approved by the Institutional Review Boards of 
the University of Pittsburgh, Baylor College of Medicine and Harris Health System.
The intervention using the Toolkit was designed to assist practices in improving uptake of 
influenza, pneumococcal and tetanus-pertussis-diphtheria (Tdap) vaccines. Vaccination rates 
for each vaccine are based on those observed in the trial and improvements in rates post 
intervention. (4) To simplify modeling procedures, we assumed that the probability of 
receiving each vaccine was not correlated with the probability of receiving other vaccines. 
We also assumed that the probabilities of receiving the two pneumococcal vaccines (23-
valent pneumococcal polysaccharide vaccine (PPSV) and 13-valent pneumococcal conjugate 
vaccine (PCV13)) were equal. This assumption was tested in sensitivity analyses.
Vaccine effectiveness (VE) was used to determine protection from illness, with illness risk 
calculated as the illness attack rate for the ≥65-year-old population multiplied by 1 minus 
VE. Influenza VE was based on medical literature and CDC data, and was varied widely to 
reflect recent trends in vaccine protection (7–9), assuming yearly revaccination. Tdap VE 
only considered pertussis prevention, due to the rarity of tetanus and diphtheria, and was 
calculated as average pertussis VE over the 10-year-model time horizon using recent data on 
waning pertussis protection post vaccination. (10) Pneumococcal vaccine effectiveness was 
similarly averaged, using waning parameters as outlined by a prior Delphi expert panel 
adjusted by observed PCV13 effectiveness from a large randomized trial (11, 12). 
Pneumococcal VE was then adjusted by the relative likelihood of disease due to each 
vaccine’s serotypes, based on published reports of U.S. epidemiologic surveillance data 
(13). PPSV was assumed to prevent invasive pneumococcal disease (IPD) from vaccine 
serotypes; PCV13 was assumed to prevent vaccine-serotype IPD and non-bacteremic 
pneumococcal pneumonia (NPP).
U.S. databases and medical literature data (7–9, 14) were used for parameters describing 
vaccine costs and effectiveness, illness rates and costs, and quality of life utilities. The 
analysis took a societal perspective, following the reference case recommendations of the 
U.S. Panel on Cost Effectiveness in Health and Medicine (15). The 4 Pillars intervention 
cost was estimated from questionnaire data obtained from intervention study sites regarding 
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personnel and material costs to introduce and maintain the intervention. Improved vaccine 
uptake was that observed at the end of the 2-year trial. All model parameters are depicted in 
Table 1.
A decision tree model was used to estimate the cost effectiveness of the Toolkit for 
improving vaccination rates compared to no intervention in persons aged 65 years and older 
(Supplementary Figure S1). Identical hypothetical cohorts traversed the two modeled 
strategies. The sum of the baseline vaccine uptake and observed percentage point 
improvement was held constant over the 10-year-model time horizon in the base case 
analysis. To account for illness-related loss of quality and duration of life, quality adjusted 
life years (QALYs) lost due to illness was used as a measure of vaccine effectiveness. Future 
costs and effectiveness were discounted at 3% per year.
To test the robustness of model results, all parameters were individually varied over the 
ranges listed in Table 1. In addition, in a probabilistic sensitivity analysis, all parameters 
were simultaneously varied over distributions 3000 times. Beta distributions approximating 
the listed ranges were assigned to probabilities and utilities; gamma distributions were used 
for costs and time lost due to illness.
Results
Based on model results considering public health outcomes (Table 2), improvements in 
vaccine uptake should lead to substantial decreases in illness frequency. Over the 10-year-
model time horizon, influenza case incidence decreased 1.8 percentage points (from 37.3% 
to 35.5% of the cohort), with comparable relative decreases in hospitalization and deaths due 
to influenza. Smaller decreases in pertussis illness, invasive pneumococcal disease and non-
bacteremic pneumococcal pneumonia occurred (0.6 PP, 0.009 PP and 0.4 PP, respectively). 
In 2014, the U.S. population aged 65 years old was 3,384,449. With an intervention program 
in place and extrapolating over 10 years, there would be approximately 60,920 fewer 
influenza cases, 2,031 fewer pertussis cases, and 13,842 fewer pneumococcal illnesses 
among this age group.
In the cost-effectiveness analysis (Table 3), total per-person vaccination and illness costs 
were $1.60 higher with the Toolkit intervention in place compared to no program, with a 
concurrent increase in effectiveness of about 0.0031 fewer QALYs lost (or about 1.1 days). 
Thus, the Toolkit cost $512 per QALY gained.
In sensitivity analyses to test the robustness of these results, no individual parameter 
variation, as listed in Table 1, caused the intervention to cost >$20,000 per QALY gained. 
Variation of only 2 parameters caused the favored strategy to change when lowering the 
threshold to $10,000/QALY gained: a) when the program-related absolute increase in 
influenza vaccination was below 0.9% (base case = 5%); or b) when influenza VE was less 
than 25.1% (base case = 59.0%). Results were insensitive to individual variation of all other 
parameters over their listed ranges. For example, if the program cost is increased to the high 
end of its range, $2.26, from its base case value of $1.78 per eligible patient, the program 
will cost $1,857/QALY gained. Increasing program costs to $5/patient will make the 
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program cost $9,533/QALY gained, while the program will be cost saving if per-patient 
costs are <$1.60. In the base case analysis, we assumed patients received both pneumococcal 
vaccines if they received any pneumococcal vaccination; if they receive both only half the 
time, the intervention will cost, at most, $2,956/QALY gained. Conversely, varying several 
parameters in clinically plausible ranges (Supplementary Figure S2) caused the intervention 
to become cost saving and more effective than no intervention, including a broad mix of 
disease incidence, vaccine effectiveness, and cost parameter variations. Finally, in a 
probabilistic sensitivity analysis, where all parameters were simultaneously varied, the 
Toolkit intervention was cost saving in 35.4% of model iterations and favored in 98.6% at a 
$50,000/QALY gained, a commonly cited cost-effectiveness benchmark (16).
Discussion
In a cost-effectiveness analysis largely based on clinical trial data, we found that an 
intervention designed to increase vaccination rates in adults cost $512 per QALY gained. In 
general, interventions costing less than $20,000 per QALY gained are considered “good 
buys,” an investment in health improvement that is very reasonable to make (17). In the 
literature and in the absence of U.S. cost-effectiveness criteria, benchmark values of $50,000 
or $100,000 per QALY gained are often cited as economically reasonable in the U.S. (16, 
18). In addition, in sensitivity analyses, individual variation of model parameters within 
plausible ranges could not increase the Toolkit intervention cost to $20,000 or more per 
QALY gained, highlighting the robustness of the intervention’s favorability. Plausible 
parameter variation could make the intervention less expensive and more effective than no 
intervention.
In prior work, we explored the cost effectiveness of hypothetical vaccination programs to 
increase influenza and pneumococcal vaccine uptake and decrease vaccination disparities in 
elderly minority patients (19–21). We found these programs economically favorable in 
general, but with higher costs per QALY gained than those found in this analysis. Those 
higher costs per QALY were driven mainly by differences in modeled program costs, 
program-related improvements in vaccine uptake, and illnesses prevented. In prior work 
examining both influenza and pneumococcal vaccines (21), programs of varying intensity 
were estimated to cost from $2 to $17.84, much more than our empiric cost $1.78 (range 
$0.70–2.26), while modeling somewhat greater improvements in vaccine uptake than those 
observed in the trial. In addition, the prior analyses modeled pneumococcal vaccine 
effectiveness only against invasive pneumococcal disease and not against non-bacteremic 
pneumonia; in the present analysis, protection against both infections is modeled.
Indirect (herd immunity) effects are not modeled in this analysis, a potential limitation. We 
justify this choice based on data suggesting that the indirect effect of vaccinating the elderly 
is much less than that seen when other age groups (e.g., children) are vaccinated, thus the 
relative indirect effect on the population of vaccinating the elderly, compared to other 
groups, is small. However, if such effects were considered, the cost effectiveness of the 
Toolkit intervention for the elderly would likely become even more favorable than the results 
reported here. The costs did not include the research personnel costs because these would 
not be included in a program using the Toolkit, but initiated by the primary care practice 
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itself. In older adults, frailty could be an important predictor of influenza vaccine 
effectiveness and influenza severity; frailty was not directly modeled, another limitation of 
our analysis.
Effectuating significant long term changes in adult vaccination rates has been an elusive 
goal. Hence, efforts to improve rates continue to be undertaken. Yet with modest short term 
improvements in vaccination uptake and limited reach of many programs, the question 
arises, “Do the improvements in vaccination rates justify the effort required by the primary 
care practice?” This cost-effectiveness analysis offers a resounding “Yes” to that question. 
At an estimated cost per eligible patient of $1.78 per year, few practices would not be able to 
implement an intervention using the 4 Pillars™ Practice Transformation Program.
We conclude that implementing an intervention based on the 4 Pillars™ Practice 
Transformation Program in an effort to increase vaccination among adults ages 65 years and 
older is a cost effective undertaking in primary care practices. Even modest improvements in 
uptake can have a large impact on the health of these at risk individuals.
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Table 1
Parameter values used in cost-effectiveness modeling
Parameter Base case Range Source
Probabilities % %
Vaccination probability with no program
 Influenza 66 36–74 (4)
 Tdap 25 4–54 (4)
 Pneumococcal vaccines 71 31–81 (4)
Absolute increase in vaccine uptake with program
 Influenza 5 0–15 (4)
 Tdap 10 0–26 (4)
 Pneumococcal vaccines 10 0–18 (4)
Vaccine effectiveness
 Influenza 59.0 20–67 (7–9)
 Tdap (10 year average) 24.5 0–95 (10)
 Pneumococcal vaccines (10 year average)
  Vaccine type invasive pneumococcal disease (IPD) 54.2 40–68 (12)
  Vaccine type non-bacteremic pneumonia (NPP) 38.3 28–48 (11, 12)
Pneumococcal illness serotype prevalence
 PCV13 serotypes 30.7 0–50 (13)
 PPSV serotypes 67.6 50–85 (13)
Probability of illness without vaccinations (yearly)
 Influenza 9.0 6.6–11.4 (22)
 Pertussis 0.257 0.138–0.464 (23)
 Invasive pneumococcal disease 0.023 0.0046–0.073 (24)
 Non-bacteremic pneumococcal pneumonia 3.78 0.54–12.1 (24)
  Relative likelihood of outpatient treatment (vs. inpatient) 83.1 70–96 (24)
Case-hospitalization, influenza 4.21 1.4–7 (22)
Case-mortality, influenza 1.17 0.37–2 (22)
Pertussis severity relative likelihood
 Mild 14 8–20 (14)
  Relative likelihood of treatment (vs. no treatment) 70.7 50–90 (14)
 Moderate 74 63–85 (14)
 Severe (hospitalized) 12 6–18 (14)
  Encephalopathy, given severe 1.43 0–3 (14)
  Mortality, given severe 0.86 0–2 (14)
Costs (base year 2015) US$ US$ US$
Vaccines
 Influenza 10.69 6.64–32.75 (25)
 Tdap 37.55 20.18–42.61 (25)
 Pneumococcal polysaccharide 7.89 2.66–13.00 (25)
 Pneumococcal conjugate 15.96 9.61–22.00 (25)
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Parameter Base case Range Source
Vaccine administration, per vaccine 25.51 20–30 (26)
Implementation program, per eligible person 1.78 0.70–2.26 a
Illness costs
 Mild pertussis, when treated 305 153–1525 (14)
 Moderate pertussis 424 212–2120 (14)
 Severe pertussis 7,824 4,000–11,500 (14)
 Influenza (average, all severities) 1,655 432–3,706 (22)
 Pneumococcal disease (average, all severities) 3,422 671–16,056 (24)
Utilities, disutilities, and durations
Utilities
 Pertussis
  Mild 0.9 0.8–0.99 (14)
  Moderate 0.85 0.75–0.95 (14)
  Severe 0.81 0.6–0.9 (14)
  Encephalopathy 0.2 0–0.4 (14)
 Non-bacteremic pneumococcal pneumonia
  Inpatient 0.2 0–0.5 (12)
  Outpatient 0.9 0.7–1 (27)
 Invasive pneumococcal disease 0.2 0.0.5 (12)
 Disability post pneumococcal disease 0.4 0.2–0.6 (12)
Disutilities (quality adjusted life years lost) QALY QALY QALY
 Non-hospitalized influenza 0.0021 0–0.02 (22)
 Hospitalized influenza 0.042 0.02–0.08 (22)
 Illness death (discounted) 10.25 5–15 (28)
Illness duration (days)
 Pertussis 87 30–100 (14)
 Non-bacteremic pneumococcal pneumonia
  Inpatient 27 20–40 (27)
  Outpatient 18 10–25 (27)
 Invasive pneumococcal disease 27 20–40 (27)
a
Calculation from unpublished 4 Pillars data
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